WLWT: UC hosts RESET epilepsy trial
WLWT recently highlighted the RESET study, a trial at the University of Cincinnati that will study a new treatment for the most severe and deadly form of epilepsy.
Brandon Foreman, MD, site principal investigator at UC for the trial being conducted across approximately 50 hospital emergency departments across the country, told WLWT the study focuses on a condition called status epilepticus (SE).
"About 10 percent of the folks who have seizures, when they come into the emergency department, are having status epilepticus," said Foreman, associate professor and associate director of neurocritical care research in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. SE is a disorder Foreman described as "seizures that don't stop."
The trial will test a new drug, ganaxolone, a neurosteroid your brain produces that can help stop seizures that won't end on their own.
"So, the promise with this medication is if you're still having seizures, despite that kind of class, one level of evidence medication...that we can give this medication and it sort of fits in at that point. Hopefully, we'll stop the seizures," Foreman said.
Featured photo at top of ambulance. Photo/Camilo Jimenez/Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.